dr. kim on combination therapies in lung cancer
Published 7 years ago • 127 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:28
dr. kim on the importance of biomarker testing for lung cancer
-
2:21
dr. kim on clinical trial eligibility criteria in lung cancer
-
1:05
edward kim, md, on anti-pd-l1/pd-1 combination therapies in treatment of lung cancer
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
1:03
dr. herbst on combination therapies for lung cancer
-
1:21
dr. kim discusses pd-l1 as a biomarker in lung cancer
-
2:11
dr. kim discusses data from the impower150 trial in nonsquamous nsclc
-
6:40
chemotherapy/immunotherapy combinations in lung cancer
-
1:17
dr. edward s. kim on his "wish list" for the future of immunotherapy in nsclc
-
11:56
dr. edward s. kim on his “wish list" for the future of immunotherapy in nsclc
-
1:14
dr. kim addresses concerns about hyperprogression in nsclc
-
1:42
dr. kim discusses the impact of the pacific trial in nsclc
-
1:55
dr. kim on combining immunotherapy and tkis in metastatic rcc
-
5:01
chemotherapy-tki combinations in metastatic egfr lung cancer
-
1:12
dr. yorio on t-dm1 in her2-mutant lung cancer treatment
-
1:58
dr. patel on combination chemotherapy and immunotherapy in lung cancer
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:35
dr. kim discusses the primary efficacy results from b-f1rst in nsclc
-
1:39
dr. gentzler on combination therapies in nsclc